bioXXmed AG

XTRA:T5O Voorraadrapport

Marktkapitalisatie: €1.4m

bioXXmed Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Mark-André Freyberg

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEO24.8yrs
Eigendom CEOn/a
Management gemiddelde ambtstermijngeen gegevens
Gemiddelde ambtstermijn bestuurgeen gegevens

Recente managementupdates

Geen updates

Recent updates

Is CytoTools (ETR:T5O) In A Good Position To Invest In Growth?

Jul 29
Is CytoTools (ETR:T5O) In A Good Position To Invest In Growth?

CytoTools AG (ETR:T5O): Are Analysts Optimistic?

May 12
CytoTools AG (ETR:T5O): Are Analysts Optimistic?

Loss-Making CytoTools AG (ETR:T5O) Expected To Breakeven In The Medium-Term

Jan 08
Loss-Making CytoTools AG (ETR:T5O) Expected To Breakeven In The Medium-Term

CEO

Mark-André Freyberg

24.8yrs

Tenure

Dr. Mark-Andr? Freyberg co-founded bioXXmed AG (formerly known as CytoTools AG) in 2000 and serves as Chief Executive Officer since 2000 and had been the Chairman of Management Board until September 30, 20...